Published in Am J Trop Med Hyg on April 01, 2010
Management of trypanosomiasis and leishmaniasis. Br Med Bull (2012) 1.78
Chagas disease: pushing through the pipeline. Nature (2010) 1.57
VNI cures acute and chronic experimental Chagas disease. J Infect Dis (2013) 1.34
Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. Curr Top Med Chem (2011) 1.27
Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Adv Parasitol (2011) 1.24
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection. Antimicrob Agents Chemother (2010) 1.22
Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. J Med Chem (2013) 1.19
Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther (2010) 1.18
Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist (2012) 1.15
Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl Trop Dis (2011) 1.15
Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. Chem Biol Drug Des (2011) 1.13
Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis (2013) 1.12
Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Negl Trop Dis (2012) 1.12
Advances in Chagas disease drug development: 2009-2010. Curr Opin Infect Dis (2010) 1.12
In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother (2013) 1.11
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging. Antimicrob Agents Chemother (2015) 1.09
Chagas heart disease: report on recent developments. Cardiol Rev (2012) 1.02
Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole. Antimicrob Agents Chemother (2011) 0.95
The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol (2012) 0.93
In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother (2012) 0.90
Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol (2013) 0.88
4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency. J Med Chem (2014) 0.88
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases. Chem Rev (2014) 0.86
Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? Expert Opin Drug Discov (2013) 0.85
Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi. Antimicrob Agents Chemother (2012) 0.84
Cellular response to Trypanosoma cruzi infection induces secretion of defensin α-1, which damages the flagellum, neutralizes trypanosome motility, and inhibits infection. Infect Immun (2013) 0.83
Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease. PLoS Pathog (2015) 0.83
Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz (2015) 0.82
Using a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotes. PLoS Negl Trop Dis (2014) 0.82
Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. PLoS Negl Trop Dis (2015) 0.80
High throughput screening for anti-Trypanosoma cruzi drug discovery. PLoS Negl Trop Dis (2014) 0.79
Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries. World J Cardiol (2012) 0.79
Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones. Mol Biol Int (2011) 0.78
Genome profiling of sterol synthesis shows convergent evolution in parasites and guides chemotherapeutic attack. J Lipid Res (2014) 0.78
Would selenium supplementation aid in therapy for Chagas disease? Trends Parasitol (2011) 0.77
Rapid Progressive Chagasic Myocarditis: A Multifactorial Condition. Am J Trop Med Hyg (2016) 0.75
Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain. Antimicrob Agents Chemother (2017) 0.75
Synthetic Medicinal Chemistry in Chagas' Disease: Compounds at The Final Stage of "Hit-To-Lead" Phase. Pharmaceuticals (Basel) (2010) 0.75
Ergosterone-coupled Triazol molecules trigger mitochondrial dysfunction, oxidative stress, and acidocalcisomal Ca(2+) release in Leishmania mexicana promastigotes. Microb Cell (2015) 0.75
The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease. Pathog Glob Health (2013) 0.75
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med (2006) 4.58
The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz (2002) 4.51
Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol (2003) 2.93
The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med (2007) 2.79
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg (1987) 2.66
Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg (1998) 2.34
Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo (2002) 2.20
Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop (2009) 2.13
Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop (2007) 2.12
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother (2003) 1.90
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop Dis (2009) 1.85
Myocardial parasite persistence in chronic chagasic patients. Am J Trop Med Hyg (1999) 1.75
Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother (1998) 1.65
Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology (1995) 1.60
Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies? Mem Inst Oswaldo Cruz (2009) 1.48
Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg (1993) 1.38
Chagas disease and the US blood supply. Curr Opin Infect Dis (2008) 1.35
Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res (2002) 1.26
Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis (2009) 1.23
Some aspects of protozoan infections in immunocompromised patients- a review. Mem Inst Oswaldo Cruz (2002) 1.20
Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg (2001) 1.18
Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz (2009) 1.15
Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant (2007) 1.11
The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med (2006) 1.06
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother (2007) 1.05
[Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases]. Rev Soc Bras Med Trop (2000) 0.97
Chronic American trypanosomiasis: parasite persistence in endomyocardial biopsies is associated with high-grade myocarditis. Ann Trop Med Parasitol (2008) 0.96
[Erythema nodoso in reactivation of Chagas' disease after cardiac transplantation]. Rev Soc Bras Med Trop (2005) 0.87
[Chagas disease and immunosuppression]. Medicina (B Aires) (1980) 0.82
[Trypanosoma cruzi high parasitemia in patient with systemic lupus erythematosus]. Rev Soc Bras Med Trop (2003) 0.81
Reactivation of Chagas' myocarditis during therapy of Hodgkin's disease. Trop Geogr Med (1992) 0.81
Comparison of Trypanosoma cruzi detection by PCR in blood and dejections of Triatoma infestans fed on patients with chronic Chagas disease. Acta Trop (2006) 0.80
Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA (2007) 2.91
The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med (2007) 2.79
Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol (2005) 2.37
Clinical profile of Trypanosoma cruzi infection in a non-endemic setting: immigration and Chagas disease in Barcelona (Spain). Acta Trop (2009) 2.13
Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop (2007) 2.12
[Antiphospholipid syndrome: analysis of 27 patients]. Med Clin (Barc) (2013) 1.98
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem (2006) 1.98
Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin Infect Dis (2009) 1.78
Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. Ann Emerg Med (2003) 1.66
Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol (2008) 1.64
Seroprevalence of Trypanosoma cruzi infection in at-risk blood donors in Catalonia (Spain). Transfusion (2008) 1.64
Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg (2006) 1.58
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum (2006) 1.53
First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother (2011) 1.48
Congenital transmission of Trypanosoma cruzi in Europe (Spain): a case report. Am J Trop Med Hyg (2006) 1.47
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) (2013) 1.46
Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob Agents Chemother (2002) 1.45
Lymphoplasmacytic lymphoma causing light chain cast nephropathy. Nephrol Dial Transplant (2012) 1.45
[Basic cardiopulmonary resuscitation program for high school students (PROCES). Results from the pilot program]. Med Clin (Barc) (2005) 1.42
Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother (2010) 1.42
Practical approach for typing strains of Leishmania infantum by microsatellite analysis. J Clin Microbiol (2002) 1.33
Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria. Malar J (2009) 1.26
Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist (2012) 1.15
Immunosuppression and Chagas disease: a management challenge. PLoS Negl Trop Dis (2013) 1.12
Etiopathogenesis of Behcet's disease. Autoimmun Rev (2009) 1.11
Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med (2007) 1.11
Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents (2004) 1.10
Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis (2002) 1.10
Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis (2013) 1.10
Socio-cultural aspects of Chagas disease: a systematic review of qualitative research. PLoS Negl Trop Dis (2013) 1.07
Imported malaria in a cosmopolitan European city: a mirror image of the world epidemiological situation. Malar J (2008) 1.07
Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum (2005) 1.07
Sterol methenyl transferase inhibitors alter the ultrastructure and function of the Leishmania amazonensis mitochondrion leading to potent growth inhibition. Protist (2007) 1.06
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology (Oxford) (2012) 1.05
A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Ann Rheum Dis (2010) 1.05
Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. J Clin Microbiol (2006) 1.05
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother (2007) 1.05
Effects of external and internal factors on emergency department overcrowding. Ann Emerg Med (2002) 1.04
Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev (2013) 1.04
Antiproliferative, Ultrastructural, and Physiological Effects of Amiodarone on Promastigote and Amastigote Forms of Leishmania amazonensis. Mol Biol Int (2011) 1.03
Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea. J Antimicrob Chemother (2009) 1.02
Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother (2004) 1.01
Diagnostic techniques to detect cryptic leishmaniasis in dogs. Clin Diagn Lab Immunol (2002) 1.01
Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents (2004) 1.00
In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob Agents Chemother (2008) 1.00
[Clinical presentation and complications of Plasmodium falciparum malaria in two populations: travelers and immigrants]. Enferm Infecc Microbiol Clin (2008) 0.99
Factors influencing polyautoimmunity in systemic lupus erythematosus. Autoimmun Rev (2009) 0.99
A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents (2010) 0.99
Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother (2007) 0.99
Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol (2007) 0.99
Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis. J Antimicrob Chemother (2005) 0.99
Magic-angle spinning (31)P NMR spectroscopy of condensed phosphates in parasitic protozoa: visualizing the invisible. FEBS Lett (2002) 0.98
Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents (2012) 0.98
Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol (2002) 0.97
Leishmania infantum DNA detection in urine from patients with visceral leishmaniasis and after treatment control. Am J Trop Med Hyg (2008) 0.97
Antiproliferative and ultrastructural effects of BPQ-OH, a specific inhibitor of squalene synthase, on Leishmania amazonensis. Exp Parasitol (2005) 0.97
Chagas disease among the Latin American adult population attending in a primary care center in Barcelona, Spain. PLoS Negl Trop Dis (2011) 0.97
Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol (2002) 0.96
Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother (2007) 0.96
Diagnosis, management and treatment of chronic Chagas' gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol (2009) 0.95
Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum (2007) 0.95
Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum (2006) 0.95
The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol (2007) 0.95
Imported malaria among African immigrants: is there still a relationship between developed countries and their ex-colonies? Malar J (2009) 0.94
A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum Mol Genet (2013) 0.94
Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother (2005) 0.94
Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int J Antimicrob Agents (2006) 0.94
Genetic structure of Phlebotomus (Larroussius) ariasi populations, the vector of Leishmania infantum in the western Mediterranean: epidemiological implications. Int J Parasitol (2010) 0.94
Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. Semin Arthritis Rheum (2007) 0.93
Value of culture and nested polymerase chain reaction of blood in the prediction of relapses in patients co-infected with leishmania and human immunodeficiency virus. Am J Trop Med Hyg (2005) 0.93
Vitamin K-dependent proteins GAS6 and Protein S and TAM receptors in patients of systemic lupus erythematosus: correlation with common genetic variants and disease activity. Arthritis Res Ther (2013) 0.93
Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem (2006) 0.93
Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2016) 0.93
Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro. J Antimicrob Chemother (2006) 0.92
Molecular surveillance of circulating dengue genotypes through European travelers. J Travel Med (2011) 0.92
Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagn Microbiol Infect Dis (2009) 0.92
Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem (2007) 0.92
Epidemiology and management of refractory lupus nephritis. Autoimmun Rev (2011) 0.92
Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". Semin Thromb Hemost (2012) 0.92
Dynamics of Leishmania-specific immunoglobulin isotypes in dogs with clinical leishmaniasis before and after treatment. J Vet Intern Med (2006) 0.91
Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera. Am J Trop Med Hyg (2012) 0.91
The glycosome membrane of Trypanosoma cruzi epimastigotes: protein and lipid composition. Exp Parasitol (2004) 0.91
In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis (2007) 0.90
Cytokine profiling in immigrants with clinical malaria after extended periods of interrupted exposure to Plasmodium falciparum. PLoS One (2013) 0.90
Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev (2013) 0.90
A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Res Ther (2012) 0.90
Effects of sterol biosynthesis inhibitors on endosymbiont-bearing trypanosomatids. FEMS Microbiol Lett (2006) 0.89
Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Ann Rheum Dis (2012) 0.89
Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol (2013) 0.89
Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev (2011) 0.89
Influence of the IL6 gene in susceptibility to systemic sclerosis. J Rheumatol (2012) 0.88
Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. Isr Med Assoc J (2006) 0.88
Hypercoagulability biomarkers in Trypanosoma cruzi -infected patients. Thromb Haemost (2011) 0.88
Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure. PLoS One (2013) 0.88
Prevalence of different virulence factors and biofilm production in enteroaggregative Escherichia coli isolates causing diarrhea in children in Ifakara (Tanzania). Am J Trop Med Hyg (2008) 0.88